2. Academic Validation
  3. Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

  • Br J Haematol. 2018 Sep;182(6):927-930. doi: 10.1111/bjh.14884.
Abraham M Varghese 1,  Andy Rawstron 2,  Darren Newton 3,  Reuben M Tooze 3,  Talha Munir 1,  Marion Dickson 4,  Gina M Doody 3,  Peter Hillmen 1
Affiliations

Affiliations

  • 1 Department of Haematology, St. James's University Hospital, Leeds, UK.
  • 2 Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
  • 3 Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • 4 Immunoinflammation Therapy Area, GlaxoSmithKline, Stevenage, UK.
PMID: 28770560 DOI: 10.1111/bjh.14884
Figures
Products